Kymera Therapeutics, Inc.

NasdaqGM:KYMR 株式レポート

時価総額：US$2.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Kymera Therapeutics マネジメント

マネジメント 基準チェック /24

Kymera Therapeutics'の CEO はNello Mainolfiで、 Jun2019年に任命され、 の在任期間は 4.58年です。 の年間総報酬は$ 9.67Mで、 6.6%給与と93.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1%を直接所有しており、その価値は$ 20.49M 。経営陣と取締役会の平均在任期間はそれぞれ3.1年と3.8年です。

主要情報

Nello Mainolfi

最高経営責任者

US$9.7m

報酬総額

CEO給与比率6.6%
CEO在任期間5yrs
CEOの所有権1.0%
経営陣の平均在職期間3.1yrs
取締役会の平均在任期間3.8yrs

経営陣の近況

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Recent updates

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31
Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Kymera KT-333 gets FDA orphan drug status for blood cancer subtype

Sep 15

Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces

Aug 15

Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M

Aug 09

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Jul 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

CEO報酬分析

Kymera Therapeutics の収益と比較して、Nello Mainolfi の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$155m

Dec 31 2023US$10mUS$640k

-US$147m

Sep 30 2023n/an/a

-US$167m

Jun 30 2023n/an/a

-US$158m

Mar 31 2023n/an/a

-US$159m

Dec 31 2022US$7mUS$600k

-US$155m

Sep 30 2022n/an/a

-US$154m

Jun 30 2022n/an/a

-US$139m

Mar 31 2022n/an/a

-US$124m

Dec 31 2021US$12mUS$571k

-US$100m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$58m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$4mUS$454k

-US$55m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$57m

Mar 31 2020n/an/a

-US$52m

Dec 31 2019US$2mUS$362k

-US$41m

報酬と市場: Nelloの 総報酬 ($USD 9.67M ) は、 US市場 ($USD 5.64M ) の同規模の企業の平均を上回っています。

報酬と収益: Nelloの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Nello Mainolfi (45 yo)

5yrs

在職期間

US$9,670,542

報酬

Dr. Nello Mainolfi, M.D., Ph D., is Co-Founder, President, Chief Executive Officer and Director at Kymera Therapeutics, Inc. since November 2019. Previously, at Kymera Therapeutics, Dr. Mainolfi served as...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Bruce Booth
Co-Founder & Independent Chairman8.8yrsUS$266.46k0%
$ 0
Nello Mainolfi
Co-Founder5yrsUS$9.67m1%
$ 19.6m
Bruce Jacobs
Chief Financial Officer4.9yrsUS$4.16m0.15%
$ 2.9m
Jeremy Chadwick
Chief Operating Officer1.1yrsUS$5.46m0.0094%
$ 183.1k
Ellen Chiniara
Chief Legal Officer & Corporate Secretary1.4yrsUS$4.97m0.0099%
$ 193.5k
Jared Gollob
Chief Medical Officer5.8yrsUS$3.47m0.089%
$ 1.7m
Karen Weisbach
Head of People & Culture2.1yrsデータなしデータなし
Juliet Williams
Head of Research3.1yrsデータなしデータなし

3.1yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: KYMRの経営陣は 経験豊富 であると考えられます ( 3.1年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Bruce Booth
Co-Founder & Independent Chairman8.8yrsUS$266.46k0%
$ 0
Nello Mainolfi
Co-Founder4.6yrsUS$9.67m1%
$ 19.6m
John M. Maraganore
Independent Director2.4yrsUS$236.46k0%
$ 0
Joanna Horobin
Independent Director6.1yrsUS$243.96k0%
$ 0
Felix Baker
Lead Independent Directorless than a yearデータなしデータなし
Elena Ridloff
Independent Director3.3yrsUS$246.46k0%
$ 0
Leigh Morgan
Independent Indepednet Director1.9yrsUS$246.46k0%
$ 0
Jeffrey Albers
Independent Director3.9yrsUS$241.46k0%
$ 0
Pamela Esposito
Independent Director3.8yrsUS$243.96k0%
$ 0
Victor Sandor
Independent Director1.6yrsUS$231.46k0%
$ 0
Gorjan Hrustanovic
Independent Director4.3yrsUS$236.46k0%
$ 0

3.8yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: KYMRの 取締役会 は 経験豊富 であると考えられます ( 3.8年の平均在任期間)。